BRIEF—Samsung Bioepis and Roche settle over Herceptin biosimilar in USA

Korean biosimilars company Samsung Bioepis has settled a US patent dispute with Roche’s Genentech, according to Yonhap News Agency.

The settlement allows for the sale of Ontruzant, a biosimilar referencing Roche’s breast cancer drug Herceptin (trastuzumab), in the USA, says a source quoted by the Korean news site.

Ontruzant won approval from the US Food and Drug Administration earlier this year.